StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas total assets

Total assets on the balance sheet at the end of each period.

Arvinas's total assets was $675.10M at Jun 30, 2026. For fiscal 2025 it was $717.90M, down 34.2% from the year before. The highest annual figure on record is $1.58B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$717.90M-34.2%
FY2024Dec 31, 2024$1.09B-16.3%
FY2023Dec 31, 2023$1.30B+2.8%
FY2022Dec 31, 2022$1.27B-19.8%
FY2021Dec 31, 2021$1.58B+120.5%
FY2020Dec 31, 2020$717.40M+137.8%
FY2019Dec 31, 2019$301.64M+51.4%
FY2018Dec 31, 2018$199.28M+198.1%
FY2017Dec 31, 2017$66.85M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$675.10M-25.8%
Q1 FY2026Mar 31, 2026$647.50M-35.3%
Q4 FY2025Dec 31, 2025$717.90M-34.2%
Q3 FY2025Sep 30, 2025$844.30M-27.7%
Q2 FY2025Jun 30, 2025$909.30M-28.9%
Q1 FY2025Mar 31, 2025$1.00B-17.4%
Q4 FY2024Dec 31, 2024$1.09B-16.3%
Q3 FY2024Sep 30, 2024$1.17B+10.3%
Q2 FY2024Jun 30, 2024$1.28B+18.1%
Q1 FY2024Mar 31, 2024$1.21B+3.1%
Q4 FY2023Dec 31, 2023$1.30B+2.8%
Q3 FY2023Sep 30, 2023$1.06B-20.7%
Q2 FY2023Jun 30, 2023$1.08B-23.0%
Q1 FY2023Mar 31, 2023$1.18B-21.0%
Q4 FY2022Dec 31, 2022$1.27B-19.8%
Q3 FY2022Sep 30, 2022$1.33B-16.8%
Q2 FY2022Jun 30, 2022$1.41B+118.5%
Q1 FY2022Mar 31, 2022$1.49B+118.3%
Q4 FY2021Dec 31, 2021$1.58B+120.5%
Q3 FY2021Sep 30, 2021$1.60B+490.1%
Q2 FY2021Jun 30, 2021$644.03M+145.3%
Q1 FY2021Mar 31, 2021$681.77M+141.4%
Q4 FY2020Dec 31, 2020$717.40M+137.8%
Q3 FY2020Sep 30, 2020$271.95M+30.1%
Q2 FY2020Jun 30, 2020$262.58M+52.6%
Q1 FY2020Mar 31, 2020$282.45M+51.4%
Q4 FY2019Dec 31, 2019$301.64M+51.4%
Q3 FY2019Sep 30, 2019$209.09M+111.4%
Q2 FY2019Jun 30, 2019$172.05M+157.4%
Q1 FY2019Mar 31, 2019$186.57M–
Q4 FY2018Dec 31, 2018$199.28M–
Q3 FY2018Sep 30, 2018$98.89M–
Q4 FY2017Dec 31, 2017$66.85M–

More Arvinas figures

See a number that looks wrong?